NGLY1 deficiency: Difference between revisions
CSV import |
CSV import |
||
| (2 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
'''NGLY1 deficiency''' is a rare genetic disorder | {{SI}} | ||
{{Infobox medical condition | |||
== | | name = NGLY1 deficiency | ||
| image = [[File:Protein_NGLY1_PDB_2ccq.png|alt=Protein NGLY1 PDB 2ccq]] | |||
| caption = Structure of the NGLY1 protein | |||
== | | synonyms = Congenital disorder of deglycosylation | ||
NGLY1 deficiency is | | pronounce = | ||
| specialty = [[Medical genetics]] | |||
| symptoms = Developmental delay, movement disorders, liver dysfunction, seizures | |||
| onset = Infancy | |||
| duration = Lifelong | |||
| causes = Mutations in the [[NGLY1]] gene | |||
| risks = | |||
| diagnosis = [[Genetic testing]], clinical evaluation | |||
| differential = Other congenital disorders of glycosylation | |||
| prevention = None | |||
| treatment = Supportive care, physical therapy | |||
| medication = | |||
| prognosis = Variable | |||
| frequency = Very rare | |||
| deaths = | |||
}} | |||
{{DISPLAYTITLE:NGLY1 deficiency}} | |||
'''NGLY1 deficiency''' is a rare genetic disorder caused by mutations in the [[NGLY1]] gene, which encodes the enzyme N-glycanase 1. This enzyme is responsible for the deglycosylation of misfolded glycoproteins in the [[endoplasmic reticulum]]-associated degradation (ERAD) pathway. The deficiency leads to a buildup of misfolded glycoproteins, resulting in a variety of clinical symptoms. | |||
== Clinical Features == | |||
Patients with NGLY1 deficiency typically present with a range of symptoms, including: | |||
* Developmental delay | |||
* [[Hypotonia]] | |||
* [[Seizures]] | |||
* [[Liver dysfunction]] | |||
* [[Movement disorders]] | |||
* [[Alacrima]] (reduced tear production) | |||
The severity and combination of symptoms can vary widely among affected individuals. | |||
== Genetics == | |||
NGLY1 deficiency is inherited in an [[autosomal recessive]] manner. This means that an affected individual must inherit two copies of the mutated gene, one from each parent. Carriers, who have only one copy of the mutation, typically do not show symptoms. | |||
== Pathophysiology == | |||
The NGLY1 enzyme plays a crucial role in the ERAD pathway by removing N-linked glycans from misfolded glycoproteins, allowing them to be degraded by the [[proteasome]]. In the absence of functional NGLY1, these glycoproteins accumulate, leading to cellular stress and dysfunction. | |||
== Diagnosis == | == Diagnosis == | ||
Diagnosis of NGLY1 deficiency is | Diagnosis of NGLY1 deficiency is typically confirmed through genetic testing, which identifies mutations in the NGLY1 gene. Biochemical assays may also be used to assess enzyme activity. | ||
== Management == | |||
== | Currently, there is no cure for NGLY1 deficiency. Management focuses on symptomatic treatment and supportive care, which may include: | ||
* Physical therapy for motor skills | |||
* Anticonvulsants for seizure control | |||
== | * Nutritional support | ||
* Management of liver dysfunction | |||
== Research == | |||
Research into NGLY1 deficiency is ongoing, with efforts focused on understanding the molecular mechanisms of the disease and developing potential therapies. Gene therapy and enzyme replacement therapy are areas of active investigation. | |||
== See also == | == See also == | ||
* [[Genetic | * [[Genetic disorders]] | ||
* [[ | * [[Endoplasmic reticulum-associated degradation]] | ||
* [[ | * [[Autosomal recessive inheritance]] | ||
[[Category:Genetic disorders]] | [[Category:Genetic disorders]] | ||
[[Category:Rare diseases]] | [[Category:Rare diseases]] | ||
Latest revision as of 02:26, 9 April 2025
Editor-In-Chief: Prab R Tumpati, MD
Obesity, Sleep & Internal medicine
Founder, WikiMD Wellnesspedia &
W8MD's medical weight loss NYC, sleep center NYC
Philadelphia medical weight loss and Philadelphia sleep clinics
| NGLY1 deficiency | |
|---|---|
| |
| Synonyms | Congenital disorder of deglycosylation |
| Pronounce | |
| Specialty | Medical genetics |
| Symptoms | Developmental delay, movement disorders, liver dysfunction, seizures |
| Complications | N/A |
| Onset | Infancy |
| Duration | Lifelong |
| Types | N/A |
| Causes | Mutations in the NGLY1 gene |
| Risks | |
| Diagnosis | Genetic testing, clinical evaluation |
| Differential diagnosis | Other congenital disorders of glycosylation |
| Prevention | None |
| Treatment | Supportive care, physical therapy |
| Medication | |
| Prognosis | Variable |
| Frequency | Very rare |
| Deaths | |
NGLY1 deficiency is a rare genetic disorder caused by mutations in the NGLY1 gene, which encodes the enzyme N-glycanase 1. This enzyme is responsible for the deglycosylation of misfolded glycoproteins in the endoplasmic reticulum-associated degradation (ERAD) pathway. The deficiency leads to a buildup of misfolded glycoproteins, resulting in a variety of clinical symptoms.
Clinical Features[edit]
Patients with NGLY1 deficiency typically present with a range of symptoms, including:
- Developmental delay
- Hypotonia
- Seizures
- Liver dysfunction
- Movement disorders
- Alacrima (reduced tear production)
The severity and combination of symptoms can vary widely among affected individuals.
Genetics[edit]
NGLY1 deficiency is inherited in an autosomal recessive manner. This means that an affected individual must inherit two copies of the mutated gene, one from each parent. Carriers, who have only one copy of the mutation, typically do not show symptoms.
Pathophysiology[edit]
The NGLY1 enzyme plays a crucial role in the ERAD pathway by removing N-linked glycans from misfolded glycoproteins, allowing them to be degraded by the proteasome. In the absence of functional NGLY1, these glycoproteins accumulate, leading to cellular stress and dysfunction.
Diagnosis[edit]
Diagnosis of NGLY1 deficiency is typically confirmed through genetic testing, which identifies mutations in the NGLY1 gene. Biochemical assays may also be used to assess enzyme activity.
Management[edit]
Currently, there is no cure for NGLY1 deficiency. Management focuses on symptomatic treatment and supportive care, which may include:
- Physical therapy for motor skills
- Anticonvulsants for seizure control
- Nutritional support
- Management of liver dysfunction
Research[edit]
Research into NGLY1 deficiency is ongoing, with efforts focused on understanding the molecular mechanisms of the disease and developing potential therapies. Gene therapy and enzyme replacement therapy are areas of active investigation.
